BIO-RAD LABORATORIES INC

For the period ended Sep 30, 2024. Filed Oct 31, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Oct 31, 2024

BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Income (Loss)

(In thousands, except per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023
Net sales	$649,729	$632,124	$1,899,025	$1,990,078
Cost of goods sold	293,826	296,441	862,037	929,495
Gross profit	355,903	335,683	1,036,988	1,060,583
Selling, general and administrative expense	200,440	201,199	610,042	634,576
Research and development expense	90,997	43,535	216,276	183,528
Income from operations	64,466	90,949	210,670	242,479
Interest expense	12,174	12,398	36,715	37,078
Foreign currency exchange (gains) losses, net	1,641	(1,680)	(2,012)	(5,280)
(Gains) losses from change in fair market value of equity securities and loan receivable	(792,888)	(36,425)	1,680,290	1,576,542
Other income, net	(18,081)	(20,446)	(70,740)	(87,365)
Income (loss) before income taxes	861,620	137,102	(1,433,583)	(1,278,496)
(Provision for) benefit from income taxes	(208,448)	(30,845)	305,185	291,464
Net income (loss)	$653,172	$106,257	$(1,128,398)	$(987,032)
Basic earnings (loss) loss per share:
Net income (loss) per share	$23.37	$3.65	$(39.89)	$(33.63)
Weighted average common shares	27,949	29,102	28,286	29,349
Diluted earnings (loss) per share:
Net income (loss) per diluted share	$23.34	$3.64	$(39.89)	$(33.63)
Weighted average common shares - diluted	27,985	29,223	28,286	29,349

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.